Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

Phase 2 Completed 22 enrolled Gem Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.

Timeline

Start: 2015-01-07
Primary completion: 2015-11-11
Completion: 2016-08-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camsirubicin	Small molecule	265 mg/m2	Intravenous

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

Summary

Timeline

Drugs

Indications